tirzepatide in the news outperformed semaglutide weight-loss drug results real world patients, study shows Kidney Outcomes in SURPASS: Exploring
Description
One of Indias biggest weight-loss drugs just got cheaper With patents expiring, #semaglutide is now flooding the Indian market with affordable generics
In patients with type 2 diabetes and high cardiovascularrisk, clinical trials have shown that GLP-1 receptor agonistsreduce the incidence of major adverse cardiovascular events.The effect of tirzepatide a dual incretin agonist of theGLP-1 and GIP receptors on cardiovascular outcomes isuncertain. In theSURPASS-CVOTtrial, patients40 years of age or older with type 2 diabetes, a BMIof at least 25, and atherosclerotic cardiovascular disease wererandomly assigned to receive a weekly subcutaneous injectionof tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), a GLP-1receptor agonist that has been shown to reduce the incidenceof cardiovascular events
Experience Medically Supervised Treatment for Lasting Results and Improved Health
Conclusion This study demonstrates that obesity-induced Th17 differentiation exacerbates neutrophilic inflammation in asthmatic mice
Calocurb has shown a low incidence of side effects in studies but mild effects can persist within the first 24-72 hours
